Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Viking Therapeutics, Inc.NASDAQ: VKTX
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 271.2% from a year ago
Cash & equivalents stood at $125.75M at the end of Q2 FY2026, up 271.2% from a year earlier and up 6.5% from the prior quarter. Over 3 fiscal years it compounded at +65.4% a year.
Context
- Cash & equivalents amounted to 24.1% of total assets at the end of Q2 FY2026, up 20.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +271.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 165.81M USD
- Year-over-year change
- +521.6%
- 4-year CAGR
- +58.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 165.81M | +521.6% |
| FY2024 | 2024-12-31 | 26.68M | -51.9% |
| FY2023 | 2023-12-31 | 55.52M | +51.6% |
| FY2022 | 2022-12-31 | 36.63M | +38.9% |
| FY2021 | 2021-12-31 | 26.37M | — |
Cash & Equivalents vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's Jun 2026 cash & equivalents of $125.75M is the 6th highest of the 7 companies compared; the peer median is $164.41M.
- Its year-over-year change of +271.2% is the highest of 6, against a peer median of -24.8%.
- Cash & equivalents amounts to 24.1% of total assets for VKTX, versus a peer median of 29.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $424.15M | -24.8% | +1.6% | 60.2% | |
| Jun 2026 | $292.73M | +57.2% | -15.7% | 23.5% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M | -47.8% | +58.0% | 27.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M | -27.5% | +46.0% | 32.3% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $130.3M | — | — | 10.8% |
| Jun 2026 | $125.75M | +271.2% | +65.4% | 24.1% | |
| Mar 2026 | $98.09M | +215.8% | +94.3% | 99.3% | |
| Peer median (excluding VKTX) | $164.41M | -24.8% | +46.0% | 29.6% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 26.37M | 36.63M | 55.52M | 26.68M | 165.81M |
| Short-term Investments | 175.73M | 118.85M | 306.56M | 875.94M | 539.93M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.81M | 8.14M | 2.52M | 1.13M | 1.81M |
| Total Current Assets | 210.53M | 167.04M | 367.23M | 907.22M | 715.6M |
| Property, Plant & Equipment (Net) | 25K | 1.42M | 1.13M | 1M | 85K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 109K | 71K | 139K | 102K | 46K |
| Total Non-current Assets | 134K | 1.49M | 1.27M | 1.11M | 131K |
| Total Assets | 210.66M | 168.53M | 368.49M | 908.32M | 715.73M |
| Account Payables | 1.44M | 8.53M | 7.51M | 9.81M | 53.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 8.78M | 21.95M | 19.14M | 27.41M | 76.67M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 1.26M | 936K | 630K | 0 |
| Total Liabilities | 8.78M | 23.21M | 20.07M | 28.04M | 76.67M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (223.18M) | (292.05M) | (377.94M) | (487.91M) | (847.55M) |
| Accumulated OCI | (549K) | (1.1M) | (389K) | (788K) | 378K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 201.88M | 145.32M | 348.42M | 880.28M | 639.06M |
| Total Debt | 29K | 1.56M | 1.26M | 1.12M | 137K |
| Net Debt | (26.34M) | (35.07M) | (54.26M) | (25.56M) | (165.67M) |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.